品管圈活动在降低乳腺癌化疗口腔炎中的应用

The Application of Quality Control Circle Activity in Reducing the Incidence of Chemotherapy Related Stomatitis in Breast Cancer Patients

目的:通过全员参与品管圈活动,制定乳腺癌化疗患者口腔护理标准流程,降低口腔炎的发生率。方法:选取2018年10月-2019年4月,在某三甲医院接受化疗的乳腺癌患者100例,平均年龄(47.23±6.77)岁(29~68岁)。所有患者随机分为两组,每组50例,一组为试验组,接受品管圈活动指导下的口腔护理;一组为对照组,接受一般口腔护理。记录两组患者经护理后口腔炎的发生率及严重程度,口腔炎发生率和严重程度的比较分别采用χ^2检验和Mann-Whitney秩和检验。结果:试验组口腔炎发病率为32%,而对照组为74%,两组差异有统计学意义(χ^2=6.83,P=0.001)。两组所有口腔炎病例均为OAGⅡ级(轻至中度口腔炎),试验组严重程度较对照组更低,且等级严重程度比较有显著性差异(Z=-4.186,P=0.00)。结论:品管圈活动大大降低了乳腺癌化疗患者口腔炎的发生率,可以推广应用于乳腺癌化疗后口腔护理。

Objective:Through the participation of all members in the quality control circle(QCC)activities,to establish the standard process of oral care for breast cancer chemotherapy patients to reduce the incidence of stomatitis.Method:From October 2018 to April 2019,100 breast cancer patients[29-68 years old,averaged(47.23±6.77)years old]who underwent chemotherapy in our department were selected in this study.All patients were randomly divided into two groups,and 50 in each group.One group was the experimental group,receiving oral care under the guidance of the QCC activity;the other group was the control group which received general oral care.The incidence and severity of stomatitis after chemotherapy were recorded in both groups.The incidence and severity of stomatitis between the two groups was tested by χ^2 test and Mann-Whitney test respectively.Result:The rate of stomatitis was 32%in the experimental group,while the control group was 74%.There was a significant difference between these two groups(χ^2=6.83,P=0.001).All cases of stomatitis in both groups were OAG gradeⅡ(mild-moderate stomatitis),and showing the severity of the test group was lower than that of the control group,the severity of the grades was significantly different between the two groups(Z=-4.186,P=0.00).Conclusion:The quality control circle activity has greatly reduced the incidence of stomatitis in breast cancer patients after chemotherapy,and it can be used as a routine oral care in chemotherapeutic patients with breast cancer.